The FDA threw its sup­port be­hind a dozen pep­tides, an­nounc­ing plans to re­clas­si­fy them, like­ly pre­sent­ing a huge mon­ey-mak­ing op­por­tu­ni­ty for what’s been a large­ly opaque mar­ket to-date...